1373010-41-3

Upstream product

• 684249-46-5 4-[(4-iodophenyl)oxy]-1-(1-methylethyl)piperidine 
• 73183-34-3 bis(pinacol)diborane 
• 352-34-1 4-fluoro-1-iodobenzene 
• 684249-45-4 4-(4-iodophenoxy)piperidine 
• 346617-98-9 1,1-dimethylethyl 4-[(4-iodophenyl)oxy]-1-piperidinecarboxylate 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 74130-05-5 4-(4-bromophenoxy)piperidine 
• 308386-38-1 tert-butyl 4-(4-bromophenoxy) piperidine-1-carboxylate 
• 106-41-2 4-bromo-phenol 
• 1373010-28-6 4-(4-bromophenoxy)-1-isopropylpiperidine 

Relevant academic research and scientific papers

Method of preparing Quinoline-5,8-dione derivatives for TGase 2 inhibitor

I Is -5,8- of the quinoline, dione derivative compound. of Formula I, or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein the compound of Formula, TGase 2 has, inhibitory effects TGase 2, and thus the pharmaceutical composition may be useful for preventing or treating disorders or diseases mediated by TGase 2 or inhibiting. (by machine translation)

Quinoline-5,8-dione derivatives for TGase 2 inhibitor, and the pharmaceutical composition comprising the same

The present invention relates to a quinolin-5,8-dione derivative compound represented by chemical formula I, an optical isomer thereof or a pharmaceutically acceptable salt thereof. The compound represented by chemical formula I of the present invention has a TGase 2 inhibitory effect, and the pharmaceutical composition comprising the same can be usefully used for preventing or treating disorders or diseases mediated by TGase 2 or response to TGase 2 inhibition.COPYRIGHT KIPO 2020

INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME

The present teaching provide indazole compounds represented by Structural Formulae (I) or (I') or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof as protein kinase inhibitors, such as T

PLK-4 INHIBITORS AND METHOD OF TREATING CANCER WITH SAME

The invention is directed to a compound represented by the following Structural Formula (I) and (II) and pharmaceutically acceptable salts thereof: (Formula (I)); (Formula (IV)). Compounds represented by this structural formula are kinase inhibitors and are, therefore, disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.